Abstract P3-12-24: PREMO CNS: PREsentation, Management and Outcomes of patients with CNS disease secondary to breast cancer in England

Résumé fourni par la source

Abstract Background: Breast cancer is the second most common primary tumour to metastasise to the brain. Improvements in the systemic treatment of extracranial metastatic disease have resulted in patients surviving longer with their metastatic disease, which appears to be contributing to the increase in the incidence of cerebral metastases. There is a need to better understand the number of patients affected, their outcomes and treatments in the context of current modern oncological treatment. Finally, it is recognised that inequality can exist with regard to treatment. This study aims to document the burden treatment and survival from CNS disease secondary to breast cancer in England utilising national cancer registry data. Study Design Methods: The study is a retrospective, cohort study using population-based registry data from The National Cancer Registration and Analysis Service (NCRAS) which is managed by NHS Digital (NHS England). Individual data on approx. 28,000 consecutive patients with CNS disease treated between 1995 and 2023 within the English Healthcare System will be utilized. Datasets utilised include: Hospital episode statistics (HES), Hospital Admitted Patient Care Activity (HESAPC), Systemic Anti-Cancer Therapy (SACT) and Radiotherapy Data Set (RTDS). Eligibility criteria: Inclusion Criteria Male or female, aged >16 years, Histologically and/or cytologically confirmed breast cancer with CNS involvement, as defined as having one or more of the following: a) Metastases to the brain parenchyma; b) Metastases to the leptomeninges c) Paraneoplastic Neurological Disorders. There were no formal exclusion criteria. This data release was approved by NHS Digital (ODR2021_030). Study Objectives: The primary objectives are to audit the overall survival from the initial diagnosis of CNS involvement secondary to breast cancer in English centres. With Secondary objectives will include to audit (1) the number of cases of metastatic breast cancer (MBC) involving the CNS presenting per year. (2) the current practice in regarding the diagnosis and management of CNS disease and (3) the outcomes of patients treated for CNS involvement secondary to breast cancer. Dara will be analysed by breast cancer subtype as well as overtime, by geographical location and by deprivation index. Citation Format: Talvinder Bhogal, Kukatharmini Tharmaratnam, Christopher Cheyne, Gary Leeming, Marta Garcia-Finana, Carlo Palmieri. PREMO CNS: PREsentation, Management and Outcomes of patients with CNS disease secondary to breast cancer in England [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-12-24.